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Inhibiting MAPK14 (p38a) diminishes cardiac damage in myocardial ischemia. During
myocardial ischemia, p38a interacts with TAB1, a scaffold protein, which promotes p38a
autoactivation; active p38a (pp38a) then transphosphorylates TAB1. Previously, we solved
the X-ray structure of the p38a-TAB1 (residues 384–412) complex. Here, we further
characterize the interaction by solving the structure of the pp38a-TAB1 (residues 1–438)
complex in the active state. Based on this information, we created a global knock-in (KI)
mouse with substitution of 4 residues on TAB1 that we show are required for docking onto
p38a. Whereas ablating p38a or TAB1 resulted in early embryonal lethality, the TAB1-KI
mice were viable and had no appreciable alteration in their lymphocyte repertoire or
myocardial transcriptional profile; nonetheless, following in vivo regional myocardial
ischemia, infarction volume was significantly reduced and the transphosphorylation of TAB1
was disabled. Unexpectedly, the activation of myocardial p38a during ischemia was only
mildly attenuated in TAB1-KI hearts. We also identified a group of fragments able to disrupt
the interaction between p38a and TAB1. We conclude that the interaction between the 2
proteins can be targeted with small molecules. The data reveal that it is possible to
selectively inhibit signaling downstream of p38a to attenuate ischemic injury.
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Introduction
The MAPK p38α is a serine threonine protein kinase that is activated by stress. The kinase is expressed in 
all mammalian cell types and is highly conserved in yeast. Ablating p38α in mice results in early embryonal 
lethality, and in yeast, it results in failures in adaptation to environmental stress and pheromones. Hence, 
p38α has an essential role in health and homeostasis (1, 2).
Nonetheless, in animal models of  acute myocardial infarction and heart failure, inhibition of  p38α 
reduces infarct size, improves left ventricular function, and limits cardiac dilatation. Conversely, cardiac-
restricted forced activation of  p38α damages the myocardium. In human hearts, p38α is activated by myo-
cardial ischemia. Thus, p38α inhibition makes therapeutic sense in ischemic heart disease (3–5).
The clinical trials that have been published to date, those that are on-going, and those that are 
planned all use pharmacological inhibitors of  p38 kinase activity that target the ATP binding site and 
inhibit the catalytic activity of  the kinase in all settings. In all cases where information is available, the 
clinical trials have been suspended due to adverse side effects such as skin and liver toxicity. The adverse 
effects are shared between inhibitors based on different scaffolds and with diverse modes of  binding to 
the ATP binding site of  p38 (3). Based on the biological importance of  this kinase, its ubiquitous expres-
sion, and the shared toxicity profile of  diverse inhibitors, the assumption is that the side effects are a 
manifestation of  on-target toxicity. Consequently, current trials are carefully designed to achieve only 
partial p38 inhibition at peak concentration. Despite this care in the controlled environment of  a clinical 
Inhibiting MAPK14 (p38α) diminishes cardiac damage in myocardial ischemia. During myocardial 
ischemia, p38α interacts with TAB1, a scaffold protein, which promotes p38α autoactivation; 
active p38α (pp38α) then transphosphorylates TAB1. Previously, we solved the X-ray structure 
of the p38α-TAB1 (residues 384–412) complex. Here, we further characterize the interaction by 
solving the structure of the pp38α-TAB1 (residues 1–438) complex in the active state. Based on 
this information, we created a global knock-in (KI) mouse with substitution of 4 residues on TAB1 
that we show are required for docking onto p38α. Whereas ablating p38α or TAB1 resulted in 
early embryonal lethality, the TAB1-KI mice were viable and had no appreciable alteration in their 
lymphocyte repertoire or myocardial transcriptional profile; nonetheless, following in vivo regional 
myocardial ischemia, infarction volume was significantly reduced and the transphosphorylation 
of TAB1 was disabled. Unexpectedly, the activation of myocardial p38α during ischemia was only 
mildly attenuated in TAB1-KI hearts. We also identified a group of fragments able to disrupt the 
interaction between p38α and TAB1. We conclude that the interaction between the 2 proteins can 
be targeted with small molecules. The data reveal that it is possible to selectively inhibit signaling 
downstream of p38α to attenuate ischemic injury.
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trial, liver toxicity is still evident, even in dosing regimens that have been carefully titrated or compro-
mised to cause only partial or suboptimal inhibition. Thus, p38 inhibition is attractive in heart disease; 
however, an alternative strategy is needed, whereby circumstance-specific inhibition of  p38α is achieved 
(6, 7). A number of  groups have shown that, during myocardial ischemia, TAB1 binds to and induces 
autoactivation of  p38α, which in turn phosphorylates TAB1. In other words, TAB1 is both an activa-
tor and a substrate of  p38α. This mechanism of  activation is independent of  MAP2K3 and MAP2K6, 
2 archetypical upstream activators of  p38α. TAB1 is a scaffold protein, the N-terminal region (residues 
1–370) is a pseudo phosphatase domain with no catalytic activity, and the C-terminal region is unstruc-
tured and contains a p38α and a TAK1 activating region (8, 9). We have previously solved the X-ray 
structure of  p38α in complex with TAB1 (residues 384–412) peptide, identified the TAB1 binding site on 
p38α, and showed the structural rearrangements within p38α induced by TAB1 (residues 384–412) that 
cause autoactivation (8, 10–12). Here, we investigated the role of  p38α and TAB1 phosphorylation on 
the interaction by solving the X-ray structure of  the complex between p38α and TAB1 (residues 1–438) 
in their phosphorylated forms. The structural data suggest that TAB1 does not dissociate from p38α after 
inducing autoactivation and becoming phosphorylated. To examine the physiological relevance of  the 
p38α-TAB1 complex, we generated a global knock-in (KI) mouse where 4 single point mutations on the 
regions of  TAB1 responsible for the interaction were mutated and prevented TAB1 from docking onto 
p38α. We used the mouse model to elucidate the role of  the interaction during myocardial ischemia in 
vivo — a setting where p38α is known to be activated through the TAB1 interaction and to cause TAB1 
phosphorylation (10). In the KI mice, the myocardial infarction volume as a percentage of  the risk vol-
ume was significantly reduced, and the ability of  active p38α to phosphorylate TAB1 was limited; howev-
er, we did not observe a major impairment of  p38α activation. Data in vitro suggest that persistent p38α 
activation may be the result of  the disinhibition of  MAP2K3 access in the absence of  TAB1 docking on 
p38α. Finally, through a fragment screen, we identified a group of  small molecules, the adamantanes, 
which bind to p38α and interfere with TAB1 recognition. This demonstrated that the interaction can be 
targeted by small molecules. Based on the results presented here, we propose that TAB1 phosphorylation 
downstream of  p38α is associated with cardiac damage during ischemia. Moreover, disabling this mode 
of  activation through the germline didn’t cause any discernible phenotype, suggesting a path to avoid the 
toxicity observed with ATP competitive inhibitors of  p38α
Results
The effect of phosphorylation on the p38α-TAB1 interaction
TAB1 binds to p38α and induces autophosphorylation of  residues Thr180 and Tyr182; active p38α is then 
able to phosphorylate TAB1 on residue Serine 423 (13). We wanted to test whether phosphorylation of  
either protein would modulate their binding affinity and/or the surface they use to interact with each 
other. To this end, we produced phosphorylated p38α (pp38α) and phosphorylated TAB1 at Serine 423 
(pS423TAB1), measured their binding affinity, solved the X-ray structure of  the complexes, and compared 
these to our previously published data on nonphosphorylated p38α and a short TAB1 (residues 384–412) 
29-mer peptide (8).
Thermodynamic characterization of the binding between pp38α-pS423TAB1, p38α-TAB1, and 
pp38α-TAB1
The binding profiles of  the interaction between p38α and TAB1, pp38α and TAB1, and pp38α and 
pS423TAB1 were very similar, irrespective of  their phosphorylation state. The conclusion is that phosphory-
lation does not affect the binding affinity between p38α and TAB1 (Figure 1 and Table 1).
Comparing p38α-TAB1 and pp38α-TAB1 X-ray structures
The X-ray structures of  pp38α and nonphosphorylated p38α with TAB1 showed that the 2 complexes used 
the same binding interface to interact with one another. The phosphorylation/activation status of  p38α had 
no material effect on the complex. TAB1 bound to the C-terminal lobe of  p38α in a bipartite manner: resi-
dues 384–394 of  TAB1 bound to a hydrophobic pocket created by αF and αH helices and the loop connecting 
helix α2L14 to helix αH (this site is defined as the noncanonical docking site [NCS] because it is specific to 
TAB1), and residues 404–412 of  TAB1 bound within the groove defined by αD and αE helices and the reverse 
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turn between β7 and β8 (this site is defined as the canonical docking site [CS] because it is also used by other 
substrates and activators of  p38α, such as MAP2K3 and MEF2A) (Figure 2). Phosphorylation did not affect 
the binding interface between p38α and TAB1; it instead induced major conformational changes of  the acti-
vation loop of  p38α, which contains the phosphorylation sites Thr180 and Tyr182 (Figure 3). In p38α-TAB1 
complex, TAB1 binding positioned the activation loop of  p38α proximal to the ATP binding site, primed 
for the autophosphorylation reaction. This was in keeping with the fact that the phosphorylation loop is the 
substrate of  the intramolecular autoactivation reaction. In pp38α-TAB1 complex, upon phosphorylation, 
the now-activated loop of  the kinase swung away from the ATP binding site, freeing access to the catalytic 
site for other substrates.
In pp38α, residue pThr180 sat at the interface between the 2 domains of  the kinase with the Thr180 
phosphate group interacting with Arg67, Arg70, and Lys66 from the N-lobe and Arg149 and Arg173 from 
the C-lobe, whereas the phosphate from pTyr182 interacted with Arg186 and Arg189 on the C-lobe. This 
loop arrangement is typical of  active kinases (Figure 4).
The crystallographic and biophysical data both suggest that TAB1 remains bound to p38α after 
having induced the kinase autoactivation and having been phosphorylated by it; they also show that no 
other region, beyond residues 384–412 in TAB1, was involved in the interaction with p38α.
Figure 1. Thermodynamic characterization of the interaction between p38α and TAB1 in their phosphorylated and nonphosphorylated forms. Top 
panels: ITC raw data of the interaction between dual (pThr180, pTyr182) phosphorylated p38α (pp38α) and TAB1 in mono (pSer423) phosphorylated (A) and 
native forms (B). Bottom panels: all but the first titration point were used for the curve fitting.
Table 1. Thermodynamic parameters for the interaction between p38α and TAB1 in their active and nonactive forms
n Kd (μM) ΔG (Kcal/mol) ΔH (Kcal/mol) –TΔS (Kcal/mol)
p38α-TAB1 (residues 384–412) 0.8 2.9 –7.5 –13.6 6.1
p38α-TAB1 (residues 1–438) 0.8 1.5 –7.9 –13.0 5.1
pp38α-TAB1 (residues 384–412) 0.8 2.0 –7.7 –13.5 5.7
pp38α-p423TAB1 (residues 1–438) 0.8 1.7 –7.9 –16.1 8.2
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Assessing the effect of TAB1 docking-site mutations on its ability to induce p38α 
autophosphorylation and to act as a substrate of p38α in bacterial and mammalian 
systems
TAB1 is a substrate of  p38α, as well as an activating binding partner (9). Mutants of  TAB1 with residue 
substitutions in each of  the 2 regions responsible for p38α binding (V390A and Y392A in the NCS and 
V408G and M409A in the CS) were created in the full-length TAB1 (residues 1–502) to examine the ability 
of  these mutants to induce autophosphorylation of  p38α and of  pp38α to transphosphorylate the mutants 
in mammalian and bacterial systems. Following IPTG induction and recombinant expression of  p38α and 
WT and mutant TAB1 proteins in transformed E.coli, phosphorylation of  p38α and TAB1 were analyzed 
by immunoblotting. WT TAB1 increased the phosphorylation of  p38α, and this was reduced by muta-
tions within TAB1. This pattern was reflected in TAB1 phosphorylation, with the lowest phosphorylation 
evident on the double mutant (Figure 5A). To complement this, a similar investigation was performed in 
mammalian cells (HEK293), with similar findings (Figure 5B). The interpretation of  the results is, however, 
complicated by the interrelation between the ability of  TAB1 to activate p38α and also to become phos-
phorylated by p38α. In other words, is the reduced phosphorylation of  the CS/NCS mutant the result of  its 
inability to activate p38α or its inability to dock on p38α? To answer this question, we coexpressed MKK3b, 
the most abundant splice variant of  MAP2K3, to equally activate p38α in the presence of  the different 
TAB1 mutants in a mammalian setting. This confirmed that the recognition regions within TAB1 needed 
to autoactivate p38α are also utilized to recognize it as a p38α substrate (Figure 5C). The in vivo cellular 
and the in vitro biophysical data are, therefore, in agreement: the TAB1 V390A/Y392A/V408G/M409A 
substitutions disabled p38α autoactivation and the ability of  p38α to transphosphorylate TAB1. The ques-
tion is whether they have similar effects on other TAB1 binding partners?
Figure 2. X-ray structure of the dual phosphorylated pp38α-TAB1 (residues 1–438) complex. TAB1 is shown in ribbon 
format (cyan) and pp38α in ribbon format (magenta) with a transparent surface overlay. The TAB1 residues belonging to 
the pseudo PP2 domain of TAB1 (residues 15–370) and the residues interacting with pp38α are visible. The N- (residues 
1–14) and C- (residues 413–438) terminal regions, the residues (residues 371–383) between the pseudo PP2 domain 
and the p38α binding region and the residues (residues 396–402) between the canonical and noncanonical site are 
disordered and not visible in the X-ray structure. The conclusion is that no other region beyond residues 384-412 of 
TAB1 interacts with p38α, confirming the ITC data of thermodynamically similar binding characteristics between TAB1 
(residues 1–438) and TAB1 (residues 384–412).
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Assessing the effect of TAB1 mutation on activation of TAK1
TAB1 is also a binding partner of  TAK1, an upstream kinase in the p38α activation pathway. TAB1 is able, 
by using 2 distinct C-terminal regions, to induce auto-activation of  p38α and TAK1. Previous reports sug-
gest that TAB1 phosphorylation acts as a negative feedback by inhibiting TAB1-induced TAK1 autophos-
phorylation and subsequent p38α phosphorylation (13). Firstly, contrary to previous reports, in HEK293 
cells, we could not clearly show that TAB1 phosphorylation alters TAK1 autophosphorylation. Then we 
examined if  the mutations within TAB1 similarly affect its ability to autophosphorylate TAK1. The mutant 
forms of  TAB1, with diminished ability to induce autophosphorylation of  p38α, were still able to efficiently 
activate TAK1. We concluded that the genetic inhibition of  the p38α-TAB1 interaction does not perturb 
TAK1 signaling (Figure 5D).
The generation of the TAB1 (V390A, Y392A, V408G, and M409A) KI mouse
p38α or TAB1 global KOs are embryonal lethal, and based on the X-ray structures of  the protein complexes 
in their active and nonactive form, we decided to create a global KI mouse with residue substitutions in each 
of  the 2 TAB1 regions responsible for p38α recognition (V390A and Y392A in the NCS and V408G and 
M409A in the CS) (1, 14). The 4 point mutations introduced in the TAB1 gene prevented TAB1 from dock-
ing onto p38α (Figure 6A and Figure 2 show the position of  the mutations on the TAB1 primary sequence 
and on the quaternary structure of  the complex, respectively). The targeting construct was made using a bac-
terial artificial chromosome (BAC) containing the mTab1 gene (GenBank accession number: NM_025609.2, 
Ensembl: ENSMUSG00000022414, https://www.ensembl.org/Mus_musculus/Gene/Summary?db=core;
g=ENSMUSG00000022414;r=15:80133127-80161707). The gene is located on mouse chromosome 15; it 
contains 11 exons with the ATG start codon in exon 1 and TAG stop codon in exon 11. The amino acid 
residues V390, Y392, V408, and M409 are located in exon 10. The targeting vector 5′ homology arm and 
3′ homology arm was amplified from BAC DNA and confirmed by end sequencing; the mutations V390A, 
Y392A, V408G, and M409A were introduced into exon 10 by site-directed mutagenesis. The constitutive 
Figure 3. Comparison of p38α bound to TAB1 peptide (residues 384–412, PDB 4LOO) and pp38α bound to TAB1 pro-
tein (residues 1–438, PDB 5NZZ). Activation of p38α induces a major shift in the conformation of the activation loop 
and the N-terminal domain rotates approximately 11° toward the C-terminal domain creating a more closed active site 
typical of activated kinases. The rest of the C-terminal domain of p38α and the p38α interacting region of TAB1 align 
closely, which is consistent with the observation that the affinity of TAB1 for p38α and pp38α is virtually identical.
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KI allele was obtained after Cre-mediated recombination, and C57BL/6 ES cells were used for gene target-
ing (Figure 6B). The ES cells bearing the integrated construct as determined by Southern blot (Figure 6C) 
were introduced into C57BL/6J mouse blastocysts and then transferred to a pseudopregnant female. The 
genomic DNA extracted from the tail clips of  PCR (Figure 6D) positive offspring was sequenced to confirm 
the presence of  the V390A, Y392A, V408G, and M409A mutations (Figure 6E).
Baseline characterization of the TAB1 (V390A, Y392A, V408G, and M409A) KI mouse
The homozygous KI mice were viable, expressed similar amounts of  the mutated form of  TAB1 as in-col-
ony WT mice, and developed normally (Figure 7, A and B). The baseline characterization shows that the 
global inhibition of  p38α-TAB1 complex formation, in all tissues and through all stages of  development, 
had no obvious consequence. The question is whether more subtle effects exist.
Targeting TAB1 (V390A, Y392A, V408G, and M409A) does not affect the cardiac 
transcriptome or the immune cell repertoire
Transcriptomic profile of  the left ventricle. We tested whether there were significant transcriptional consequences 
to expressing TAB1 (V390A, Y392A, V408G, and M409A) in mouse left ventricular myocardium. We per-
formed RNA-sequence (RNA-Seq) analysis of  KI versus WT heart and observed no major transcriptional 
differences. The highest log2-fold change detected was 0.75; in fact, only 27 genes out of  the approximately 
14,000 detected showed a log2-fold difference in either direction of  greater than 0.5. All other genes showed 
fold differences below 0.5. When the list of  differentially expressed genes with a P adjusted value below 0.05 
is analyzed through the Reactome database pathway (https://reactome.org/); the only biological pathway 
that shows a significant overrepresentation in the list of  genes is the circadian clock system. Finally, none of  
the known genes involved in p38α signaling were differentially expressed (15).
Our interpretation is that, at baseline, beyond the circadian clock pathway, there is no significant bio-
logical difference in the transcriptome profile of  the WT vs. KI hearts (Figure 7C and Table 2).
Immunophenotype
p38α is expressed in, and regulates the function of, several classes of  immune cells. Of  most relevance, 
p38α autophosphorylation plays a role in T lymphocyte maturation, including through TAB1 (16, 17). 
We therefore examined and compared the repertoire of  immune cell populations in the spleen, BM, and 
Figure 4. Comparison of p38α and pp38α activation loops in the complexes. This comparison illustrates the reorienta-
tion of Y182 and movement of T180 away from the ATP binding site upon phosphorylation. For clarity, only the ATP-γ-S 
ligand of the pp38α structure is shown.
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Figure 5. Characterizing the interaction between p38α and wild type (WT) and mutated forms of TAB1 by co-expression. (A) Overexpression of p38α 
and TAB1 in E.Coli. Coexpression of TAB1 and p38α increases p38α and TAB1 phosphorylation. Mutation of each of the individual recognition sites in TAB1 
diminishes these phosphorylations with the strongest effect apparent when both sites are mutated. (B) Similar results are obtained with overexpression 
of p38α and TAB1 in HEK293. (C) Overexpression in HEK293 cells of p38α, TAB1, and MKK3b in an attempt to normalize the levels of p38α activation. The 
data show that the recognition regions within TAB1 that are needed to autoactivate p38α are also those used to present TAB1 as a p38α substrate. (D) 
Stopping TAB1 from docking onto p38α does not affect the ability of TAB1 to activate TAK1. One-way ANOVA was used for the statistical analysis, *P < 
0.05, **P < 0.01 vs. p38α/TAB1 WT.
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mesenteric lymph nodes in WT vs. KI mice (Figure 7D). These analyses did not reveal any statistically 
significant differences in macrophage or lymphocyte abundance or maturation.
Myocardial ischemia and infarction in TAB1 (V390A, Y392A, V408G, and M409A) KI mice
Ischemia activates p38α, and pharmacological inhibition of  p38α during ischemia reduces heart damage. Our 
group has previously shown that, during ischemia, p38α is activated through autophosphorylation induced 
by the interaction with the scaffold protein TAB1 (8, 11, 12). Here, we subjected WT and KI mice to in vivo 
regional ischemia to measure the activation of  p38α, TAB1 phosphorylation, and subsequent infarct size.
As previously reported in the literature, ischemia causes p38α activation and TAB1 phosphorylation 
(Figure 8) (18, 19). We did not observe significant differences in the levels of  p38α activation between WT 
and KI hearts at 5 minutes. At 10 minutes, there appeared to be slightly less p38α activation in KI hearts, but 
the magnitude of  this difference was small (Figure 8B). In contrast, the amount of  TAB1 phosphorylation 
was strikingly and significantly lower in the KI hearts. Thus, while p38α was activated in the KI hearts, it 
was unable to transphosphorylate TAB1 (Figure 8C). We concluded that, in the KI hearts, a compensatory 
mechanism is in place, which allows p38α activation despite inhibition of  p38α-TAB1 complex formation.
Figure 6. Creation of the TAB1 (V390A,Y392A,V408G and M409G) KI mouse. (A) TAB1 protein sequence, the targeted residues are shown in red. (B) 
Targeting strategy to produce the TAB1 (V390A, Y392A, V408G, and M409A) KI mouse. Schematic representation of the WT allele, targeted allele, and the 
constitutive KI allele after Cre recombination. (C) Southern blot of WT and 2 targeted ES cell clones (denoted as 2C9 and 2E10) with 3 probes. The expected 
molecular weight band for WT and the targeted allele are shown. (D) PCR of the targeted allele using genomic DNA derived from tail snips. (E) Sequencing 
of the genomic DNA of the targeted allele confirming the 4 single point mutations.
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We also observed that, in the KI hearts, following 30 minutes of  regional ischemia and 120 minutes 
of  reperfusion, myocardial infarction volume as a percentage of  the risk volume was significantly reduced 
(Figure 9, A and B). We hypothesize that the protective phenotype we observed in the KI hearts can be 
associated, at a molecular level, to the abolition of  TAB1 phosphorylation.
A possible compensatory mechanism to explain p38α activation during myocardial 
ischemia in TAB1 (V390A, Y392A, V408G, and M409A) KI mice
A caveat with our genetic approach is that we stopped TAB1 from docking onto p38α in all circumstances, 
but by doing so, MAP2K3 and MAP2K6, the archetypical upstream activators of  p38α, may have unhin-
dered access to p38α, possibly participating in a compensatory mechanism that could explain the activation 
of  p38α observed in the KI mice. For example, the interaction points of  MKK3b, the most abundant splice 
variant of  MAP2K3, on p38α have previously been described and partially overlap with those of  TAB1 (8, 
20, 21). We therefore examined if  TAB1 and MKK3b peptides can compete for access to p38α based on 
the polarization of  fluorescence of  C-terminal labelled MKK3b peptide (Figure 9, C and D). From this, it 
is clear that labeled MKK3b peptide is displaced by TAB1 peptide and that the affinity of  TAB1 for p38α is 
at least as great as that of  unlabeled MKK3b peptide. We conclude that TAB1 and MKK3b bind competi-
tively to p38α and that, by preventing TAB1 from docking onto p38α under all circumstances, we may have 
freed access for MKK3b to p38α.
Figure 7. (A) Growth curves comparing within colony WT and KI mice. Mouse weights taken between 5 and 12 weeks of age from each genotype 
were analyzed using 2-way repeated measures ANOVA. Weights are not significantly different. (B) Immunoblot analysis of total TAB1 expressed in 
organs of WT vs. KI mice. (C) Volcano plot showing minimal changes of the transcriptome profile between WT and KI hearts. (D) Immune phenotype 
characterization. Each data point represents a cell subset. MLN, mesenteric lymph nodes; SPLN,spleen. The position of the data point on the x axis 
represents how the mean size of that subset changes in the KI relative to the WT. The position of each data point on the y axis represents the 1/P 
value. The dotted horizontal line represents the Bonferroni adjusted threshold for statistical significance. None of the populations are statistically 
different between KI and WT mice.
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Targeting the noncanonical site of p38α-TAB1 interaction with small molecules
As part of  a concerted fragment screen, we identified a group of  functionalized adamantanes that bound 
to one of  the hydrophobic pockets on the surface of  p38α that forms the NCS for TAB1. Adamantanes 
consist of  3 fused cyclohexanes that form a stable cage where almost any carbon can be functionalized. 
We focused our investigations on the 3-amino-1-adamantanol (Figure 10A). The X-ray structure of  the 
complex revealed that the 3-amino and 1-oxydryl group of  the adamantane formed hydrogen bonds with 
the oxygens of  the backbone carbonyl of  leucine 222 and 234, respectively. The rest of  the cage also had a 
good surface complementarity with the aforementioned hydrophobic pocket (Figure 10B). To validate this 
crystallography data in solution, we ran a fluorescence-based thermal shift assay with p38α. The thermal 
shift assay showed that the adamantate stabilizes the kinase (ΔTm = 3.1 °C), relative to DMSO control. 
In addition, this binding was independent of  the ATP-binding pocket, since the stabilization caused by 
3-amino-1-adamantanol in the presence (ΔTm1 = 3.1 °C) or in the absence (ΔTm2 = 3.3 °C) of  SB220025, 
Table 2. Pathway analysis using reactome
Pathway name Entities found Entities total Entities ratio Entities P value Entities FDR
BMAL1: CLOCK, NPAS2 activates circardian gene 
expression
21 70 0.005 1.11 × 10–16 4.59 × 10–14
Circadian Clock 25 99 0.007 1.11 × 10–16 4.59 × 10–14
NR1D1 (REV-ERBA) represses gene expression 5 10 0.001 3.02 × 10–6 8.32 × 10–4
RORA activates gene expression 7 38 0.003 2.16 × 10–5 4.46 × 10–3
FDR < 0.05 was considered significant.
 
Figure 8. (A) Immunoblot analysis of heart homogenates taken from hearts subjected to regional myocardial ischemia at 5 and 10 minutes. (B) Quantification 
of phosphorylated p38α normalized against total p38α. WT control vs. WT and control vs. KI at 5 minutes, ***P < 0.001; WT control vs. WT at 10 minutes, *P < 
0.05. (C) Phosphorylated TAB1 normalized against total TAB1. WT control vs. WT 10 minutes, ***P < 0.001; WT vs. KI at 10 minutes, ††††P < 0.0001. As previously 
reported in the literature, ischemia causes p38α activation and subsequent TAB1 phosphorylation in the WT hearts. In the KI heart, TAB1 phosphorylation is 
almost completely abolished during ischemia, despite the nearly equivalent activation of p38α.
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a high-affinity ATP competitive inhibitor, was similar (Figure 10C). We then ran an in vitro kinase assay 
with pp38α and TAB1 in the presence and in the absence of  3-amino-1-adamantanol, and we show that 
the ligand is able to interfere with the ability of  pp38α to phosphorylate TAB1 (Figure 10D).
Discussion
We have created a KI mouse harboring 4 residue substitutions in TAB1 that prevent docking onto p38α. The 
effect is a reduction in myocardial ischemic injury following coronary artery occlusion, despite only mini-
mal reduction of  p38α activation. We also observed an almost complete abolition of  TAB1 phosphorylation 
during cardiac ischemia, confirming that the disruption of  the p38α-TAB1 complex occurs in vitro. Our 
hypothesis is that, at a molecular level, the association between TAB1 and p38α drives ischemic damage.
A tool compound that is able to disrupt the interaction between p38α and TAB1 would enable studies to 
be extended to other species and organs, while permitting temporal control. To this end, our structural data 
provide a deep understanding of the interaction between the 2 proteins both in their active and nonactive states. 
The main structural finding is that phosphorylation does not perturb the surface nor the strength of their inter-
action, suggesting that pTAB1 remains bound to active p38α. Based on our data, we can be confident that any 
tool compound targeting the surface of the interaction would be active, regardless of the phosphorylation state 
of the proteins. We identified the adamantanes as binders of the noncanonical site on the kinase and showed 
that they inhibit TAB1 phosphorylation in vitro. This careful analysis of the p38α surface involved in the inter-
action supports the concept that the p38α-TAB1complex can be targeted by small molecules, which could 
ultimately form the basis of a novel class of protein-protein inhibitor (PPI) molecules.
Finally, the genetic model shows that inhibiting the interaction between p38α and TAB1 throughout 
development is not lethal, suggesting that drugging the interaction will not have the liabilities associat-
ed with ATP-competitive inhibitors of  p38α kinase activity. The cardioprotection we observed in our KI 
Figure 9. Myocardial infarction in TAB1 WT and KI mice, and competition between TAB1 and MKK3b on p38α. (A) 
Myocardial infarction volume (INF) as a percentage of the risk zone (RZ) in the area at risk (AAR) of the left ventricle 
(LV) is significantly reduced in KI mice after 30 minutes of occlusion of the left anterior descending coronary artery and 
120 minutes of reperfusion (29.4% ± 2.0% vs. 22.2% ± 1.4%, n = 12, **P < 0.01). (B) Infarction area plotted against RZ 
area measured on heart slides as described in Methods confirming the decreased susceptibility to ischemic injury in KI 
mice. P < 0.05 vs. WT. Fluorescence polarization titration revealing the displacement of fluorescein-labeled MKK3b by 
unlabeled MKK3b (C) or TAB1 (D). One-way ANOVA and 1-way ANCOVA used.
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mouse model and the fact that all of  the binding affinity between the 2 proteins was concentrated on a 
defined surface (the CS and NCS on p38α and a stretch of  29 amino acids on the C-terminal region of  
TAB1) encourages the development of  PPI molecules to recapitulate the benefits of  genetic inhibition.
Methods
Protein expression and purification. DNA encoding mouse p38α was derived from a pET14b vector donated by 
Y. Wang (University of  California, Los Angeles) and subcloned into a pETDuet-1 vector. The full coding 
sequence included an N-terminal His6 tag followed by a TEV-cleavage site and mouse p38α sequence. The 
vector was transformed in E. coli strain Rosetta II cells (Novagen). To produce milligram quantities for the 
structural studies of  dual phosphorylated p38α, we ran a large-scale in vitro kinase activation using recom-
binant constitutively active mkk6DD. The activated p38α was them purified from the reaction mixture, and 
mass spectrometry was used to confirm stochiometrical phosphorylation of  p38α. The protein expression, 
in vitro activation, and purification procedures followed are described in refs. 22 and 23.
Chemically synthesized DNA encoding mouse TAB1 was subcloned into a pETDuet-1 vector. The 
full coding sequence included an N-terminal His6 tag followed by a TEV-cleavage site and mouse TAB1 
(residues 1–438). The vector was transformed in E. coli strain Rosetta II cells. Recombinant TAB1 (residues 
1–438) was expressed and purified according to the same protocols used for p38α.
To overexpress and purify pS423TAB1 (residues 1–438), we followed ref. 24. Briefly, C321(DE3)ΔserB 
E. coli cells were transformed with the pCDF vector containing pS423TAB1 (residues 1–438), recovered with 
1 ml super optimal broth (SOB) medium, and plated on a streptomycin/chloramphenicol agar plate. The 
Figure 10. TAB1 and 3-amino-1-adamantanol compete for the same hydrophobic pocket on the noncanonical site 
of p38α. (A) 3-Amino-1-adamantanol binding site. The hydrophobic pocket on p38α is shown as a semitransparent 
surface, the 3-amino-1-adamantanol molecule is shown in magenta. The hydrogen bonds between the 3-amino group 
and the hydroxyl group of the adamantane and the oxygens of the backbone carbonyl of Leu 222 and Leu 234 are 
shown as dotted lines. The van der Waals surface of the adamantanol is shown as a mesh in magenta. (B) Zoom-in of 
the noncanonical site in pp38α-TAB1 complex, the hydrophobic pocket used by the 3-amino-1-adamantanol is shown 
in identical representation and orientation as in A. TAB1 is shown in ribbon form (cyan) with the side chains of Arg 
384, Val 385, and Tyr 386 shown. (C) Representative fluorescence based thermal shift assay of p38α (5 μM) with DMSO 
baseline control (green) vs. 12.5 mM 3-amino-1-adamantanol (orange) and DMSO + 50μM SB220025 (blue) vs. 12.5 mM 
3-amino-1-adamantanol + 50μM SB220025 (red). Inset: Box and whisker representation indicating that 3-amino-1-ada-
mantanol binding is not competitive to the high-affinity ATP competitive inhibitor SB220025. (D) Western blot analysis 
of pp38α-TAB1 IVKA in the presence and in the absence of 12.5 mM 3-amino-1-adamantanol. It shows that the ligand 
prevents pp38α phoshorylation of TAB1.
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protocols to grow, express, and purify pS423TAB1 (residues 1–438) are the same as the ones used for TAB1 
and p38α; the only difference is that the cells were grown in the presence of  2 mM O-phospho-L-Serine.
ITC. All ITC experiments were carried out on an iTC200 microcalorimeter from Microcal (GE Health-
care). The integrated heat data for the titrations corrected for heats of  dilution were fitted with a nonlinear 
least-squares minimization algorithm to a theoretical titration curve, with MicroCal-Origin 7.0 package. 
ΔH° (reaction enthalpy change in kcal mol−1), Kb (equilibrium binding constant in M−1), and n (molar ratio 
between the 2 species in the syringe and calorimetric cell) were the fitting parameters. The reaction entropy 
was calculated with the relationships ΔG = −RT × lnKb (R =1.987 cal mol−1 K−1, T=298 K) and ΔG = 
ΔH − TΔS, where ΔH represents molar enthalpy change, ΔS represents molar entropy change, and ΔG 
represents molar Gibbs free energy change..
X-ray crystallography. TAB1 and pp38α proteins were purified in 20 mM Tris pH 7.5, 100 mM NaCl, and 
10 mM MgCl2 buffer and concentrated to 10 and 20 mg/ml, respectively. The 2 proteins were mixed in the 
molar ratio of  1.05 TAB1:1.0 pp38α and ATP-γ-S (Tocris Bioscience) added to 10 mM; the final concentra-
tion of  the complex was 8 mg/ml. Crystallisation screens were set up using a Mosquito dispensing system 
and a single hit condition obtained (#B12-Proplex screen: 0.1 M MgCl2, 0.1 M Na HEPES pH7.0 and 
15% PEG4000, Molecular Dimension). In-house testing showed the crystals were not cryoprotected and 
diffracted weakly to approximately 3.5 Å. Grid optimizations of  PEG/buffer percentage and type were set 
up together with additive screens; resultant crystals were subjected to various cryoprotection strategies, flash 
frozen in liquid nitrogen, and tested at Diamond Light Source
Final, optimized crystals were grown from 20% 1:1 PEG4000/PEG6000, 50 mM MgCl2, 50 mM 
MgSO4, and 0.1 M Tris pH 8.0 and were cryoprotected by rapid transfer through well solution supple-
mented with 20% ethylene glycol and diffracted to 2.6 Å.
Initial screening of  crystals was carried out in-house using an Xcalibur Nova rotating copper anode 
system with Onyx CCD. Final data were collected at the Diamond synchrotron, beamline IO4.1, 25 Hz 
Pilatus 6M-F detector. Data were integrated and scaled using Aimless (25), solved by molecular replace-
ment using Phaser (26) with PDBs 4LOO (p38α) and 2J4O (TAB1). The resultant model was refined to 
completeness by 5 alternating cycles of  manual rebuilding in Coot (27) and refinement with Refmac (28). 
Final statistics and the coordinates have been deposited in the Brookhaven Protein DataBank, PDB code 
5NZZ (https://www.rcsb.org/structure/5NZZ).
Cell biology. pETDuet-1 vector was used for bacterial coexpression of  p38α and the different TAB1 
mutants: TAB1 (residues 1–502), TAB1 (residues 1–502) with noncanonical site mutations V390A and 
Y392A, TAB1 (residues 1–502) with canonical site mutations V408G and M409A, and p38-TAB1 (resi-
dues 1–502) with canonical and noncanonical site mutations V390A, Y392A, V408G, and M409A. In all 
the bacterial vectors, p38α was subcloned in the first multiple-cloning site, whereas TAB1 was subcloned in 
the second multiple-cloning site. 
Liposome-mediated transfection of  HEK293 cells. HEK293 cells were transfected with plasmids express-
ing WT p38α, WT TAB1, mutant forms of  TAB1, WT TAK1, and WT MKK3. Cells were placed into 
serum free media (SFM) prior to transfection with complexes containing Turbofect reagent (Thermo 
Fisher Scientific, catalog R0531) and plasmid DNA. Transfection complexes were prepared and allowed 
to combine at room temperature for 20 minutes and were then made up to a volume of  1 ml and added 
drop-wise to cells. Transfection complexes were left on cells overnight and then aspirated and replaced 
with SFM. Cells were harvested 24 hours after transfection.
TAB1 (V390A, Y392A, V408G, and M409A) KI mouse generation. The targeting vector 5′ homology arm 
and 3′ homology arm was amplified from BAC DNA and confirmed by end sequencing; the mutations 
V390A, Y392A, V408G, and M409A were introduced into exon 10 by site-directed mutagenesis with Qui-
kChange Site-Directed Mutagenesis Kit (Agilent Technologies). The targeting construct was electroporated 
into C57BL/6 ES cells, 375 G418-resistant colonies were picked, and the PCR assays were performed 
with primers 5PCR_F and 5PCR_R. Thirty-four potential targeted clones were identified. Six of  them 
were expanded and frozen. The Southern blot analysis was conducted with 5′-probe, 3′-probe, and Neo-
probe. The genomic DNA of  the potential clones were digested with Bg1II for the 5′-probe and analyzed 
by Southern blot for a 8.0-Kb band from the WT allele and a 10.0 Kb band for the recombinant allele; for 
the 3′ probe, the genomic DNA was digested with XmaI and analyzed by Southern blot for a 7.8-Kb band 
from the WT allele and a 5.7-Kb band for the recombinant allele. Regarding the Neo probe, the genomic 
DNA was digested with NsiI and analyzed by Southern blot for a 6.6-Kb band for the recombinant allele.
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TAB1 (V390A, Y392A, V408G, and M409A) F1 mice were generated from the ES cell lines 2C9. Five 
(3 males and 2 females) out of  8 pups were identified as positive by PRC screening: the expected 261-bp 
fragment from WT allele and 405-bp fragment from recombinant allele were represented as positive F1 
mice. The primers used for the screening were: Neo_Del_F and Neo_Del_R.
The primers sequences used were: 5PCR_F: 5′-GCGGAGTATTAGGAGCCTGAGGGT-3′, 5PCR_R: 
5′-GCTGACCGCTTCCTCGTGCTTTA-3′, 5′-probe_F: 5′-CAGCCACTTGTGAGACCAGAGGA-3′, 
5′-probe_R: 5′-GGACAAGCCTGTGAGGTGATGACA-3′, 3′-probe_F: 5′-GGTCCCTCACAAGGGT-
TAAGCAACT-3′, 3′-probe_R: 5′-GAACTTGTCTGTGCTCTGAGCTGGC-3′, Neo-probe_F: 5′-CCT-
GAATGAACTGCAGGACGAGG-3′, Neo-probe_R: 5′-AGCTCTTCAGCAATATCACGGGTAGC-3′, 
Neo_Del_F: 5′-GCTGGCCTTGCTCAACTCCAG-3′, Neo_Del_R: 5′-GACCATCTGTCTCATACCT-
GACCTCAC-3′.
Library preparation and next-generation sequencing. RNA isolated from the 10 left ventricles (5 for each 
condition: WT vs. KI) was quantified using Qubit fluorometric quantification and assessed for quality 
using Agilent Bioanalyzer. Library preparation was performed using NEBNext Ultra Directional RNA 
Library Prep Kit for Illumina and the NEBNext rRNA Depletion kit (New England BioLabs). The library 
was sequenced on an Illumina HiSeq2500 at the Genomic Centre at King’s College London (paired-end, 2 
× 125 bps, >25 M reads per samples, HiSeq SBS Kit V4).
RNA-Seq data analysis. RNA-Seq data of  mouse heart cell populations were obtained as paired-end 
reads. Each sample contained typically 10–11 million reads. Sequence reads were aligned to the Ensembl 
GRCm38 genome using TopHat2 (29); alignment rates were 82.9% ± 1.9%. Transcripts were counted using 
the featureCounts program. Data analysis was performed in the R environment (R Core Team 2016). The 
matrix of  merged transcript counts (30) was processed with a quality filter to remove genes with no counts 
in any cell sample. The dimension of  the final data matrix was 14,864 genes by 10 samples. The entire 
RNA-Seq data flow was managed by a GNU make pipeline. Transcript counts were further analyzed for 
differential gene expression using the DESeq2 package (31).
The RNA-Seq data have been deposited in Annotare 2.0 webserver, https://www.ebi.ac.uk/fg/, entry 
code: E-MTAB-6460
Immunophenotype. Single cell suspensions from spleen were prepared by mechanical disruption using 
Miltenyi C-tubes, followed by enzymatic digestion in PBS Ca2+/Mg2+, 2% FCS (v/v), 10 mM HEPES, 
Collagenase (1 mg/ml), and DNAse (0.1 mg/ml) 37°C for 30 minutes. Cells were isolated from mesenteric 
lymph nodes using manual mechanical disruption followed by enzymatic digestion (as above) for 15 min-
utes at 37°C. BM immune cells were isolated from the femur by centrifugation (5,000 g). Spleen and BM 
RBCs were lysed using RBC lysis buffer (eBioscience) for 90 seconds at room temperature. All samples 
were incubated with FC block (clone 2.4G2, BD Biosciences) for 10 minutes at 4°C prior to staining with 
live/dead dye (Zombie NIR; BioLegend) for 10 minutes at room temperature. Samples were then stained 
with the following antibody panels at 4°C for 20 minutes. T cell panel; CD45 Qdot 605, CD5 BV510, TCR-
d Pe-Cy7, CD161/NK1.1 BV650, CD4 BV786, CD8 AF700, CD25 APC, GITR PE, CD44 FITC, CD62L 
PerCP-Cy5.5, KLRG1 BV421. Myeloid panel; CD45 Qdot 605, CD11c BV786, CD11b BV510, F4/80 
PerCP-Cy5.5, Ly6C AF700, Ly6G APC, CD103 PE, CD317 BV650, MHCII/IA/IE FITC, CD86 PE-
Cy7, (lineage) CD3, CD19, NK1.1 BV421. B Cell Panel; CD45 Qdot, IgG1 PE, B220 (CD45R) AF-700, 
IgM BV786, IgD PerCP-Cy5.5, GL-7 AF647, CD95 PE-Cy7, CD138 BV650, CD5 BV510, CD21/35 
FITC, CD23 BV421. NK/myeloid panel; CD19 Pe-Cy7, CD5 APC, Ly6G APC, Ly6C AF700, MHCII/
IA/IE FITC, CD11c BV786, CD161/NK1.1 BV650, CD21/35 PE, CD11b BV510, CD23 BV421. Bone 
marrow panel; CD45 Qdot 605, CD43 PerCP-Cy5.5, GR1 AF700, CD11b BV510, B220/CD45R Pe-Cy7, 
CD24 APC, CD138 BV650, BP1/Ly51 PE, CD3 BV785, IgD AF488, IgM BV421 (antibody information 
is detailed in Supplemental Table 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.121144DS1). Samples were acquired using a BD Fortessa X20 equipped with 405 
nm, 488 nm, 561 nm and 644 nm lasers. Data was analyzed using DIVA software (BD Biosciences), and 
plots were produced in R using the ggplot2 package. 
In vivo ischemia/reperfusion and measurement of  the myocardial infarction volume as a percentage of  the risk 
volume. Animal studies used age-matched (12–14 weeks old) WT and TAB1 KI male mice (Cyagen Biosci-
ences). Mice were placed inside an induction chamber, where 4% isoflurane was provided with an oxygen 
flow rate of  0.5 l/min until loss of  righting reflex. Anesthetized mice on a vertical support suspended by 
its upper incisors were intubated by inserting a 20-G cannula through the trachea. Artificial ventilation of  
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the lungs was provided with a mouse respirator (Hugo Sachs Elektronic MiniVent Type 845) set at 200 
μl of  stroke volume and at 150 strokes per minute venting 2% isoflurane. A rectal probe was inserted to 
monitor and to adjust the homeothermic warming pad to maintain the temperature at 37°C ± 1°C. The 
thorax was exposed and an incision was performed in the third intercostal space. Then, the operating 
region was exposed by using chest microretractors. Temporary ischemia of  the left ventricle was achieved 
by placing a 0.2 cm PE90 tube parallel to the left anterior descending coronary artery (LAD) and looping 
an 8-0 nylon suture (Ethilon, Johnson & Johnson) around both tube and LAD. The PE90 tube and the knot 
were released 30 minutes after ischemia, leaving a loose suture in the area where the occlusion took place. 
Reperfusion was confirmed visually by the return of  blood flow back into the myocardium. To assess the 
area at risk, the loose suture left around the LAD was tightened after 2 hours of  reperfusion, and 300 μl 
of  3% Evans Blue (3% w/v in 0.9% v/w NaCl) was injected in the left ventricle via the apex to delineate 
the risk zone (RZ). Heart samples were collected by excising and snap-freezing the whole heart, which was 
then cut into 750-μm sections from apex to base using a custom mouse block. All slices were incubated at 
37°C for 20 minutes with 3% w/v 2,3,5-triphenyltetrazolium chloride (MilliporeSigma) dissolved in 0.1 M 
Na2HPO4/NaH2PO4 buffer adjusted to pH 7.4. Slices were fixed overnight in 10% formaldehyde and then 
placed between 2 cover slips and digitally imaged using a high-resolution optical scanner (Epson). Images 
were analyzed using ImageJ (SciJava), and the size of  infarcted area, left ventricle area at risk, and nor-
mally perfused left ventricle zone were outlined in each section by identification of  their appearance and 
borders. Areas were quantified on both sides of  each slice and averaged. Infarct size (INZ) was calculated 
as a percentage of  RZ for each heart. To produce ischemic hearts for the biochemical analysis, permanent 
ischemia was performed by directly tightening the LAD with a double knot; heart samples were collected 
by cutting and snap-freezing the apex 5 and 10 minutes after occlusion.
Western blot analysis of  p38α, TAB1, pp38α, and pTAB1 in ischemic heart homogenate. Rapidly snap-frozen 
apex samples were homogenized in a cold glass pestle and mortar tube containing chilled buffer (50 mM 
Tris-HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 1% Triton X100, 0.1 % β-mercaptoethanol, 1 mM Na3VO4, 
50 mM NaF, 5 mM Na4P2O7, and 1 protease inhibitor cocktail tablet per 50 ml [cOmplete, Roche Diagnos-
tics]). Homogenates were centrifuged (16,000 g) at 4°C for 10 minutes, and supernatants were collected and 
added to 2× SDS buffer (20% glycerol, 6% SDS in 0.12 M Tris pH 6.8, 10% 2-mercaptoethanol, and 0.4% 
Bromophenol blue) and boiled for 10 minutes. Samples were resolved on 10% SDS PAGE gels under dena-
turing conditions and transferred onto PVDF membranes. After blocking in 4% nonfat milk and 1% BSA in 
Tris-buffered saline, pH 7.4, for 1 hour, membranes were exposed to the following primary antibodies over-
night at 4°C, with agitation: anti–dual phospho-p38 (Thr180 and Tyr182, 9211, Cell Signaling Technology), total 
p38 (9212, Cell Signaling Technology), anti–phospho TAB1Ser423, and total TAB1 (both from MRC PPU 
reagents, S739A, S823A). After washing and incubation with HRP-conjugated secondary antibody, antigen-
antibody complexes were visualized by enhanced chemiluminescence detection (Pierce Biotechnology).
MKK3 competitive binding assay. A titration of  TAB-1 (Ac-RVYPVSVPYSSAQSTSKTSVTLSLVMPSQ-
NH2) or MKK3b (Ac-GKSKRKKDLRISCMSKP-NH2) peptide was dispensed from a concentrated solution 
in DMSO using a Hewlett Packard D300 digital dispenser directly into a 384-well low-volume assay plate. 
The DMSO concentration was normalized to 1% of the final assay volume. To this was added a mixture of  
2 nM fluorescein-labeled MKK3b peptide (Ac-GKSKRKKDLRISCMSKPK[ε-fluorescein]-NH2) and 10 μM 
p38α in a buffer of  50 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM Chaps, and 1 mM DTT. The final well 
volume was 10 μl. After incubation at ambient temperature for 20 minutes, fluorescence polarization was 
measured on a Perkin Elmer multimode reader (480 nm excitation filter, 535 nm emission filters, 505 nm 
mirror). Data were normalized between averaged control wells of  DMSO only (0% displacement) and ligand 
only (100% displacement). Duplicate titrations were averaged and fitted to a 4-parameter IC50 function.
Thermal shift assays. Thermal shift assays were performed using an Agilent MX3005p quantitative 
PCR (qPCR) instrument with 70 cycles at 1°C interval from 24°C–94°C. Samples were prepared by 
mixing recombinant purified p38α with buffer (40 mM Tris pH7.5, 100 mM NaCl, and 4 mM DTT) and 
ligands ± DMSO to normalize the DMSO level to 2.5% in all samples. Samples were incubated at room 
temperature for 30 minutes prior to assays. Sypro Orange (Invitrogen, S6651, 5,000× concentrate in 
DMSO) was separately prepared at 1:1,000 dilution in the same buffer and then mixed 1:1 with the pro-
tein/ligand samples just prior to the thermal shift assays. The final concentration in the assays was 5 μM 
p38 ± 12.5 mM 3-amino-1-adamantanol (Fluorochem ) ± 50 μM SB220025 (MilliporeSigma). Melting 
curves were analyzed using PRISM and Tm values calculated using the Boltzmann sigmoidal function. 
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Each experiment was performed 9 times, and mean ΔTm values calculated for DMSO vs. 3-amino-
1-adamantanol (ΔTm1) and SB220025 vs. SB220025 + 3-amino-1-adamantanol (ΔTm2).
In vitro kinase assay. An in vitro kinase assay was performed with recombinant active p38α and TAB1 
(residues 1–438), and 3 μM of  pp38α was incubated with 15 μM of  TAB1, with or without 12.5 mM 
3-amino-1-adamantanol. The reaction was carried out in 1× kinase buffer (25 mM Tris/HCl pH 7.5, 5 
mM β-glycerolphosphate, 2 mM DTT, 0.1 mM Na3VO4, and 1 mM MgCl2). ATP (550 μM) was added 
to the incubation mixture to start the reaction at 37oC for 2 hours. At the end of  reaction, the samples 
were collected with 2× sample buffer (20% glycerol, 6% SDS in 0.12 M Tris pH6.8, 10% 2-mercapto-
ethanol, and 0.4% Bromophenol blue), heated to 95°C for 10 minutes, and run on 10% SDS gel under 
denaturing conditions. The samples were transferred onto a PVDF membrane using semidry technique, 
blocked with 4% milk + 1% BSA for 1 hour at room temperature, and probed with appropriate primary 
antibody overnight at 4°C. The blots were probed with appropriate secondary antibody linked with 
HRP and visualized by enhanced chemiluminescence. Antibodies used included anti–dual-phosphor-
ylated p38 (Thr180/Tyr182) (M8177, MilliporeSigma; 9211, Cell Signaling Technology) at 1:5,000, 
total p38 (9212, Cell Signaling Technology) at 1:10,000, anti–phosphorylated TAB1 (Phil Cohen group, 
University of  Dundee) at 1:2,000.
Statistics. The statistical analysis used when comparing multiple groups was 1-way or 2-way ANOVA, 
as indicated in the figures legend. For repeated measures when comparing multiple measurements within 
subjects (Figure 7, C and D), the Bonferroni correction was used to adjust the threshold for statistical 
significance. A 1-way ANCOVA test was used for Figure 9B. P < 0.05 was considered significant.
Study approval. This investigation was performed in accordance with the Home Office Guidance on the 
Operation of  the Animals (Scientific Procedures) Act 1986, published by Her Majesty’s Stationery Office 
(London, United Kingdom). Animals were maintained humanely in compliance with the “Principles of  
Laboratory Animal Care” formulated by the National Society for Medical Research and the Guide for the 
Care and Use of  Laboratory Animals (National Academies Press, 2011). All animal protocols were approved 
both by the local King’s College Animal Welfare and Ethical Review Board and by the UK Government 
Home Office (Animals Scientific Procedures Group).
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